609 related articles for article (PubMed ID: 19417570)
1. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
2. [Antivasoproliferative agents in ophthalmology].
Ambresin A; Zografos L; Mantel I
Rev Med Suisse; 2010 Jan; 6(231):51-4. PubMed ID: 20196434
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
5. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
7. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
8. Preferred therapies for neovascular age-related macular degeneration.
Chiang A; Regillo CD
Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
[TBL] [Abstract][Full Text] [Related]
9. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
10. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Shah GK; Sang DN; Hughes MS
Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF therapy: comparison of current and future agents.
Pieramici DJ; Rabena MD
Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
14. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
15. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
Kaiser PK
Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860
[TBL] [Abstract][Full Text] [Related]
16. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
Farah SE
Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
[TBL] [Abstract][Full Text] [Related]
17. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Nelson M
Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
[No Abstract] [Full Text] [Related]
18. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
20. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
